Meta-Analysishigh evidence
Varenicline for nicotine cessation in youth: A meta-analysis of randomized controlled trials addressing FDA labeling gaps in age and product use.
Journal of substance use and addiction treatment·September 1, 2026·PMID 42044870
Why it mattersVarenicline is FDA-approved for adults but lacks clear guidance for youth. This analysis addresses that gap, showing efficacy and safety in young nicotine users, which may inform off-label use and future trials in adolescents and young e-cigarette users.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled